Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer

Steven Lehrer, Peter H. Rheinstein, and Kenneth E. Rosenzweig

Islam and colleagues report that sildenafil suppresses inflammation-driven colorectal cancer in mice (1). Intestinal cyclic guanosine monophosphate (cGMP) signaling regulates epithelial homeostasis and has been implicated in the suppression of colitis and colon cancer. In their study, Islam and colleagues demonstrated that the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil can prevent cancer in the azoxymethane/dextran sulfate sodium inflammation-driven colorectal cancer mouse model.

Here, we use data from The Cancer Genome Atlas (TCGA) to assess survival of colon cancer patients with and without mutations of the PDE5A gene. We assessed the association between PDE5A and colon cancer overall survival using the GDC TCGA Colon Cancer (COAD) cohort in TCGA database. To access and analyze the data, we used the UCSC Xena browser (https://xenabrowser.net). Survival data of the mutant and unmutated PDE5A subgroups were extracted for analysis and generation of Kaplan–Meier curves for overall survival.

Data from 371 patients were analyzed. The tumors were all primary, and each patient had only one tumor. The mean age at diagnosis was 67.1 ± 13.1 (mean ± SD). A total of 51.9% were male, 48.1% were female. 52.4% were white, 14.2% were African American, 2.5% were Asian, and 30.6% were unreported. A total of 359 patients had an unmutated PDE5A gene. Twelve patients had a mutant PDE5A gene. The PDE5A gene had one or more of these mutations:

- Frameshift variant
- Stop gained
- Splice acceptor variant
- Missense variant
- Synonymous variant
- Splice region variant

Ten of the 12 mutant PDE5A genes had a single mutation. One of the mutant genes had two mutations (stop gained + missense); the other had three mutations (stop gained + 2 missense).

Survival of colon cancer patients is shown in Fig. 1. A total of 359 patients with no mutation of PDE5A had significantly poorer survival than 12 patients with mutation of PDE5A. The effect of the mutation is significant (log-rank 3.814, $P = 0.05$).

Chronic inflammation is involved in many forms of cancer. Aspirin and other NSAIDs reduce the risk of multiple cancer types due to their anti-inflammatory properties. Another NSAID, sulindac, inhibits the development of cancer through PDE5 suppression. Sildenafil is a small molecule that inhibits PDE5. The study of Islam and colleagues validates PDE5 as a colon cancer chemoprevention target in mice (2), as did a second mouse study (3). Our analysis of TCGA data corroborates this finding in humans. Further studies are needed to determine whether sildenafil or other PDE5 inhibitors might be colon cancer preventives or treatments.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received March 25, 2018; revised April 16, 2018; accepted April 25, 2018; published first xx xx, xxxx.
References


AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

Q1: Page: 1: AU: Per journal style, genes, alleles, loci, and oncogenes are italicized; proteins are roman. Please check throughout to see that the words are styled correctly. AACR journals have developed explicit instructions about reporting results from experiments involving the use of animal models as well as the use of approved gene and protein nomenclature at their first mention in the manuscript. Please review the instructions at http://aacrjournals.org/content/authors/editorial-policies#genenomen to ensure that your article is in compliance. If your article is not in compliance, please make the appropriate changes in your proof.

Q2: Page: 1: Author: Please verify the drug names and their dosages used in the article.

Q3: Page: 1: Author: Please verify the edits made in the article title for correctness.

Q4: Page: 1: Author: Please verify the affiliation for correctness.

Q5: Page: 1: Author: Please verify the corresponding author's details.

Q6: Page: 1: Author: Please confirm quality/labeling of all images included within this article. Thank you.

Q7: Page: 1: AU./PE: The conflict-of-interest disclosure statement that appears in the proof incorporates the information from forms completed and signed off on by each individual author. No factual changes can be made to disclosure information at the proof stage. However, typographical errors or misspelling of author names should be noted on the proof and will be corrected before publication. Please note if any such errors need to be corrected. Is the disclosure statement correct?

AU: Below is a summary of the name segmentation for the authors according to our records. The First Name and the Surname data will be provided to PubMed when the article is indexed for searching. Please check each name carefully and verify that the First Name and Surname are correct. If a name is not segmented correctly, please write the correct First Name and Surname on this page and return it with your proofs. If no changes are made to this list, we will assume that the names are segmented correctly, and the names will be indexed as is by PubMed and other indexing services.

<table>
<thead>
<tr>
<th>First Name</th>
<th>Surname</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven</td>
<td>Lehrer</td>
</tr>
<tr>
<td>Peter H.</td>
<td>Rheinstein</td>
</tr>
<tr>
<td>Kenneth E.</td>
<td>Rosenzweig</td>
</tr>
</tbody>
</table>